Salvia Bioelectronics

Salvia BioElectronics is a medical device company with a mission that is simultaneously scientific and deeply human: to give people who live with migraine their lives back. For the hundreds of millions of people worldwide who experience this debilitating neurological condition — from the episodic attacks that disrupt days to the chronic forms that can make normal life functionally impossible for weeks at a time — existing treatment options often provide incomplete, inconsistent, or only temporary relief, frequently carry significant side effects that limit long-term adherence, or fail entirely in the most severe and refractory cases where the burden of disease is greatest. Salvia was founded on the conviction that a fundamentally different therapeutic approach is both necessary and achievable. The company is developing an implantable neuromodulation device designed specifically for migraine treatment — a bioelectronic therapy that uses precisely targeted electrical stimulation to modulate nerve activity and interrupt the pathophysiological processes that drive migraine attacks. The approach draws on a growing and clinically robust body of evidence that the sphenopalatine ganglion — a key nerve cluster in the skull intimately connected to the pain pathways and autonomic processes that characterize migraine — can be therapeutically influenced to abort acute attacks and, with appropriate treatment protocols, reduce their frequency and severity over time. Salvia's device is engineered to deliver this stimulation with the clinical precision, long-term reliability, and patient-controlled usability that a real-world implantable therapeutic product must achieve to gain clinical adoption and patient acceptance. As a pioneer in the field of bioelectronic medicine, the company brings together deep clinical expertise in neurology and pain medicine, rigorous medical device engineering, and access to well-characterized patient populations through its clinical partner network — providing both the evidence generation capacity and the institutional credibility needed to navigate the demanding regulatory approval processes for implantable devices in major markets. The broader ambition behind Salvia's work reaches beyond any single product: to establish bioelectronic medicine as a recognized and widely available therapeutic modality in clinical neurology, beginning with migraine — where the unmet need is enormous, well-documented, and commercially significant — with the potential to expand the approach to other conditions where carefully targeted nerve modulation has shown therapeutic promise. Growth strategy is built around clinical validation milestones, regulatory submissions, and the development of deep partnerships with academic medical centers, hospital neurology departments, and medical device technology integrators that will support the transition from a development-stage device to a broadly available clinical therapy.